Allergan Valeant

Allergan rejects Valeant’s improved offer

Published: 00:02, June 11, 2014

Allergan rejects Valeant’s and hedge fund billionaire William Ackman’s improved $53 billion acquisition offer. The Botox maker has stood its ground since Valeant Pharmaceuticals International Inc. and Pershing Square Capital Management jointly made a bid in April.

Pershing, a company that Ackman founded, has a 9.7% share in Allergan. On May 28th, Pershing and Valeant improved their offer and then raised it again on May 30th. In the second offer, Pershing agreed to take a lower price for its Allergan shares to help up the bid. Mr. Ackman said he would ask Allergan shareholders to vote.

The latest offer includes $72 in cash plus 0.83 Valeant shares, making it worth approximately $177 per share.

Based in Irvine, California, Allergan Inc. operates in more than 100 countries.

Valeant offer undervalues Allergan

On Tuesday, Allergan again turned down the offer saying that it undervalues the company and is not in the best interest of its shareholders. Allergan also commented on Valeant’s business model, describing its financial data as “opaque”.

The value of Valeant shares are questionable, Allergan says, because it is unique among specialty drugmakers in failing to report sales of individual medications in its earnings report.

In a letter to Valeant’s CEO Michael Pearson, David Pyott, CEO of Allergan wrote:

“After thorough consideration, the Allergan Board has unanimously determined that your second revised proposal substantially undervalues Allergan, creates significant risks and uncertainties for the stockholders of Allergan, and is not in the best interests of Allergan and its stockholders.”

“In addition, we do not believe your latest proposal offers sufficient or certain value to warrant discussions between Allergan and Valeant.”

Valeant to approach Allergan shareholders

Laurie Little, a Valeant spokeswoman, said her company will now take the deal to shareholders for a vote, the aim being to replace the current Allergan board of directors with Valeant-friendly members. If this does occur, it will probably not be before November.

Ms. Little said:

“Valeant’s offer to combine with Allergan will create substantial value for both companies’ shareholders, and we look forward to giving Allergan shareholders the opportunity to speak for themselves.”

In an interview with Reuters, Mr. Pyott said he was in for the long slog “I’m an endurance player; I climbed Kilimanjaro last year.” Allergan has $14 billion in cash flow which he claims shareholders would like to use for acquisitions. If Allergan made acquisitions it would deter Valeant from pursuing its acquisition quest.

Valeant shuts down R&D

According to Valeant, Allergan spends too much money on research and development (R&D) of medications. It believes Valeant’s costs would be reduced and sales boosted if the two companies, which specialize in dermatological products, joined. Rather than spending on R&D, Valeant has a tendency to buy firms with proven treatments.

Two years ago, Valeant acquired Medicis Pharmaceutical Corp. Then the Medicis staff were gathered together and given envelopes. A black envelope meant the employee was fired. Most of Medicis’ R&D team received the black envelopes. It was not long before the thirty or so ongoing research projects were cancelled.

Acquiring companies, focusing on selling their successful products and stripping down their R&D, has helped Mr. Pearson increase Valeant’s annual sales to $5.8 billion in 2013, six times what it was in 2008 when he took the helm. During the six-year period, Valeant’s shares have risen 848%.

Mr. Pearson, who has spent about $19 billion taking over companies since 2008, says he wants Valeant to become one of the big five global drugmakers by 2006.

Christian Nordqvist Avatar

Other News

Why the weather can affect ratings of cold-weather gear

Nov 15, 2026

Seeing a purchase as part of a collection can change the shopping experience

Nov 15, 2026

Retail app ads may influence what customers do after installation

Nov 15, 2026

A bank tested AI customer twins for marketing, with mixed lessons for businesses

Nov 15, 2026

What makes a product vintage, and why the distinction matters to retailers

Nov 15, 2026

EU business social media use rises, but a gap remains by company size

Nov 15, 2026

Why startups may benefit from testing locally before expanding abroad

Nov 14, 2026

Novel product ideas can be harder to try but more rewarding afterward

Nov 14, 2026

What is in an online cart can influence whether shoppers check out

Nov 14, 2026

Subscription plans can miss customers who would save money, Lyft research finds

Nov 14, 2026

Workers with worse shifts than their colleagues were more likely to leave, restaurant study finds

Nov 14, 2026

More product options do not always reach more customers, cosmetics study finds

Nov 14, 2026

EU household spending grew in 2025 as communication purchases led gains

Nov 13, 2026

Ad experiments can help predict which campaigns drive additional sales

Nov 13, 2026

Browser choice screens lifted Firefox usage in Europe, researchers find

Nov 13, 2026

Online product rankings can cut shipping costs without reducing sales, experiment finds

Nov 13, 2026

Large companies lead EU service exports, but smaller firms dominate in some markets

Nov 13, 2026

Cart reminder timing is linked to different shopper responses

Nov 12, 2026

AI labels changed how consumers judged food images in three experiments

Nov 12, 2026

Shared AI tools were linked to higher sales for small online sellers

Nov 12, 2026